MELANIE SIMS: Open Payments
NPI 1093956351 · CARROLLTON, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,215 in 48 payments from 15 companies in 2025. Trend: 2023 $19 · 2024 $1,216 · 2025 $1,215
Food & beverage: $1,215
| Company | Payments | Amount |
|---|---|---|
| Phathom Pharmaceuticals, Inc. | 5 | $191 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 10 | $188 |
| PFIZER INC. | 8 | $151 |
| Aimmune Therapeutics, Inc. | 2 | $149 |
| GENZYME CORPORATION | 4 | $117 |
| ABBVIE INC. | 5 | $100 |
| Janssen Biotech, Inc. | 3 | $87 |
| Ardelyx, Inc. | 2 | $43 |
| Lilly USA, LLC | 2 | $41 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $39 |
Products named: VOQUEZNA, XIFAXAN, ZENPEP, DUPIXENT, VELSIPITY, TREMFYA, XELJANZ, CREON.
Industry payments across GA — which companies pay providers there.
